CNTX logo

Context Therapeutics Inc

CNTX

$1.16

+ $0.16 (16.00%) This month

Closed: 23 Feb 2024 21:00 US/Eastern

Key details

CEO

-

Employees

6

Headquarters

Philadelphia, United States

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

About Context Therapeutics Inc

context therapeutics is dedicated to discovering, acquiring, and developing novel compounds to treat hormone responsive cancers. our lead program is apristor (onapristone xr), an investigational drug for progesterone receptor positive (pr+) breast cancer. up to 70% of breast cancers express progesterone receptor (pr). if your cancer is pr+, apristor could be an option for you.

Please treat this data as an indicator only since we can't always guarantee that it's accurate or complete. Bear in mind too that the prices you'll see are delayed by at least 15 minutes. Intraday pricing and company data provided by IEX.
Finimize
© Finimize Ltd. 2023. 10328011. 280 Bishopsgate, London, EC2M 4AG